Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Unleashing the Power of Ephedrine Hydrochloride: A Comprehensive Review on R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Ephedrine Hydrochloride, the Mechanism of Action for Ephedrine Hydrochloride, and the drug target R&D trends for Ephedrine Hydrochloride.
Advanced Tech.
7 min read
A type of emerging tumor treatment drug: Aptamers
19 September 2023
Aptamers are short nucleotide sequences, typically DNA or RNA of 20 to 100 nucleotides.
Drug Insights
4 min read
A Comprehensive Review of Eliglustat's R&D Innovations and Drug Target Mechanism
18 September 2023
This article summarized the latest R&D progress of Eliglustat, the Mechanism of Action for Eliglustat, and the drug target R&D trends for Eliglustat.
Latest Hotspot
3 min read
Lisata Therapeutics reports the initial treatment of a patient in the BOLSTER Trial involving LSTA1, for patients with solid tumors
18 September 2023
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively.
Drug Insights
4 min read
Pharmaceutical Insights: Doripenem's R&D Progress and its Mechanism of Action on Drug Target
18 September 2023
This article summarized the latest R&D progress of Doripenem, the Mechanism of Action for Doripenem, and the drug target R&D trends for Doripenem.
Valuable Targets
5 min read
Regulating tumor immune suppression, the therapeutic effect of the new generation CSF-1R inhibitors is encouraging
18 September 2023
CSF-1 exerts its effects by binding to a receptor called colony stimulating factor 1 receptor (CSF-1R), also known as c-FMS, leading to a signaling pathway cascade.
Drug Insights
4 min read
Exploring Dihydroergotamine Mesylate's Revolutionary R&D Successes
18 September 2023
This article summarized the latest R&D progress of Dihydroergotamine Mesylate, the Mechanism of Action for Dihydroergotamine Mesylate, and the drug target R&D trends for Dihydroergotamine Mesylate.
Latest Hotspot
3 min read
CheckMate-227 Trial Phase 3 confirms prolonged survival with Opdivo and Yervoy in Metastatic Non-Small Cell Lung Cancer
18 September 2023
Phase 3 CheckMate-227 Trial's findings confirm enduring, extended survival with Opdivo combined with Yervoy with Metastatic Non-Small Cell Lung Cancer.
Drug Insights
4 min read
Decoding Diacerein: A Comprehensive Study of its R&D Trends
18 September 2023
This article summarized the latest R&D progress of Diacerein, the Mechanism of Action for Diacerein, and the drug target R&D trends for Diacerein.
Advanced Tech.
7 min read
Important anti-cancer drug for tackling tumors: saRNA drug
18 September 2023
Due to the small molecular weight and gene specificity of saRNA, it can be used to enhance the expression of specific proteins (products of tumor suppressor gene or haploinsufficient genes).
Drug Insights
4 min read
Deep Scientific Insights on Dabigatran Etexilate Mesylate's R&D Progress
18 September 2023
This article summarized the latest R&D progress of Dabigatran Etexilate Mesylate, the Mechanism of Action for Dabigatran Etexilate Mesylate, and the drug target R&D trends for Dabigatran Etexilate Mesylate.
Latest Hotspot
3 min read
Blue Earth Therapeutics reports encouraging findings from preclinical assessment of 225Ac-rhPSMA-10.1 of Prostate Cancer
18 September 2023
Blue Earth Therapeutics released preclinical study results on the potency, lipophilicity, absorption, and efficacy of 225Ac-rhPSMA-10.1 in prostate cancer models, compared to 177Lu-rhPSMA-10.1. Both showed strong binding, excellent absorption, and similar lipophilicity.